- Home
- EDTK vs CRIS Comparison
EDTK vs CRIS Comparison
Compare EDTK & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | CRIS |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 14.6M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EDTK | CRIS |
|---|---|---|
| Price | $0.90 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 7.1K | ★ 114.9K |
| Earning Date | 01-14-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $893,690.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.80 | $1.02 |
| 52 Week High | $1.20 | $4.50 |
Technical Indicators
Market Signals| Indicator | EDTK | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 40.13 |
| Support Level | $0.80 | $1.29 |
| Resistance Level | $0.95 | $1.41 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 35.73 | 23.54 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.